BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
Mass spectrometry identification solution may help hospitals manage antimicrobial resistance more effectively FRANKLIN LAKES, N.J., Apr. 27, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global distribution of a complete portfolio of products for mass spectrometry that provides high-speed and high-confidence identification of pathogens in... Read more